Table 2.
Patients characteristics related to core mutation type, univariate analysis
| Characteristics | Patients with DW-type infection n = 13 | Patients with R70Q/H and/or L91M substitutions n =95 | Patients with L91M substitution n = 40 | Patients with R70Q/H substitution n = 8 | P value1 |
| Age (yr) | 51.5 | 53.6 | 53.3 | 50 | a = 0.607 |
| median | (29.1-66.54) | (22.1-68.3) | (24.4-67.3) | (33.8-58.8) | b = 0.694 |
| c = 0.860 | |||||
| Gender | 7 (53.8) | 57 (60) | 22 (55) | 5 (62.5) | a = 0.767 |
| Female (%) | b = 1.000 | ||||
| c = 1.000 | |||||
| Residence | 11 (84.6) | 67 (70.5) | 33 (82.5) | 5 (62.5) | a = 0.509 |
| Urban (%) | b = 1.000 | ||||
| c = 0.325 | |||||
| Baseline ALT (mg/dL) | 94 | 76 | 78 | 67 | a = 0.592 |
| median | (3-235) | (16-890) | (17-890) | (54-197) | b = 0.849 |
| c = 1.000 | |||||
| Baseline HCV-RNA (log10IU/mL), median | 6.25 | 6.05 | 6.05 | 6.3 | a = 0.966 |
| (4.15-6.9) | (4.15-7.3) | (4.1-7.3) | (5.2-7.1) | b = 1.000 | |
| c = 0.414 | |||||
| Mild/moderate fibrosis (F1 + F2, %) | 4 (57.1) | 34 (58.6) | 14 (58.3) | 4 (57.14) | a = 0.881 |
| b = 0.925 | |||||
| c = 0.283 | |||||
| IL28B CC (%) | 6 (46.2) | 13 (13.7) | 8 (20.0) | 1 (12.5) | a = 0.011 |
| b = 0.080 | |||||
| c = 0.174 | |||||
| RVR (%) | 6 (46.2) | 8 (8.4) | 4 (10.0) | 0 (0.0) | a = 0.002 |
| b = 0.009 | |||||
| c = 0.005 | |||||
| EVR (%) | 10 (76.9) | 33 (34.7) | 15 (37.5) | 3 (37.5) | a = 0.005 |
| b = 0.024 | |||||
| c = 0.164 | |||||
| SVR (%) | 10 (76.9) | 32 (33.7) | 15 (37.5) | 2 (25.0) | a = 0.005 |
| b = 0.024 | |||||
| c = 0.032 |
1
P value symbols a, b, c: cases from each category type of viral substitutions (columns 3, 4, 5) vs cases without viral mutation [double wild-type (DW)-type - column 2]. HCV: Hepatitis C virus; SVR: Sustained virological response; EVR: Early virological response; RVR: Rapid virologic response.